David L. Veenstra
Affiliations: | Pharmacy | University of Washington, Seattle, Seattle, WA |
Area:
General, Epidemiology, General EconomicsGoogle:
"David Veenstra"Children
Sign in to add trainee| Mitchell K. Higashi | grad student | 2001 | University of Washington |
| Nina Oestreicher | grad student | 2004 | University of Washington |
| Jennie H. Best | grad student | 2007 | University of Washington |
| Lisa M. Meckley | grad student | 2008 | University of Washington |
| Mindy M. Cheng | grad student | 2012 | University of Washington |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hendrix N, Oestreicher N, Lalla D, et al. (2022) Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model. Clinical Breast Cancer |
| Hendrix N, Veenstra DL, Cheng M, et al. (2021) Assessing the Economic Value of Clinical Artificial Intelligence: Challenges and Opportunities. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 25: 331-339 |
| Neuberger EE, Carlson JJ, Veenstra DL. (2020) Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome. Pharmacoeconomics |
| Dhanda DS, Veenstra DL, Regier DA, et al. (2020) Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment. Journal of Managed Care & Specialty Pharmacy. 26: 529-537 |
| Veenstra DL, Mandelblatt J, Neumann P, et al. (2020) Health Economics Tools and Precision Medicine: Opportunities and Challenges. Forum For Health Economics & Policy |
| Basu A, Carlson J, Veenstra D. (2020) Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 23: 96-103 |
| Guzauskas GF, Basu A, Carlson JJ, et al. (2019) Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 988-994 |
| Niu X, Amendola LM, Hart R, et al. (2019) Clinical exome sequencing vs. usual care for hereditary colorectal cancer diagnosis: A pilot comparative effectiveness study. Contemporary Clinical Trials. 84: 105820 |
| Veenstra DL, Guzauskas G, Peterson J, et al. (2019) Cost-effectiveness of population genomic screening. Genetics in Medicine : Official Journal of the American College of Medical Genetics |
| Li M, Basu A, Bennette C, et al. (2019) How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 777-784 |